{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:08:19Z","timestamp":1758478099601,"version":"3.41.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["320030_143867"],"award-info":[{"award-number":["320030_143867"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.jhep.2014.03.026","type":"journal-article","created":{"date-parts":[[2014,3,28]],"date-time":"2014-03-28T18:24:45Z","timestamp":1396031085000},"page":"293-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Rivaroxaban postmarketing risk of liver injury"],"prefix":"10.1016","volume":"61","author":[{"given":"Stefan","family":"Russmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Niedrig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Budmiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Stieger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"H\u00fcrlimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd A.","family":"Kullak-Ublick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2014.03.026_b0005","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/asheducation-2013.1.464","article-title":"Pros and cons of new oral anticoagulants","volume":"2013","author":"Bauer","year":"2013","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.1016\/j.jhep.2014.03.026_b0010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40265-013-0174-4","article-title":"Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism","volume":"74","author":"Burness","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.jhep.2014.03.026_b0015","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/11586600-000000000-00000","article-title":"Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery","volume":"34","author":"Watkins","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.jhep.2014.03.026_b0020","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2014.03.026_b0025","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs\u2013I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jhep.2014.03.026_b0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4254\/wjh.v6.i1.17","article-title":"Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment","volume":"6","author":"Teschke","year":"2014","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2014.03.026_b0035","unstructured":"AG BS. Xarelto\u00ae Fachinformation; 2013. Available from: http:\/\/www.swissmedicinfo.ch."},{"key":"10.1016\/j.jhep.2014.03.026_b0040","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.tpj.6500458","article-title":"Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis","volume":"8","author":"Kindmark","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jhep.2014.03.026_b0045","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/heartjnl-2013-305288","article-title":"Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis","volume":"100","author":"Caldeira","year":"2014","journal-title":"Heart"},{"year":"1995","series-title":"The binomial distribution fundamentals of biostatistics","author":"Rosner","key":"10.1016\/j.jhep.2014.03.026_b0050"},{"key":"10.1016\/j.jhep.2014.03.026_b0055","unstructured":"Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. In: U.S. Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Silver Spring, MD, USA: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration; 2009. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM174090.pdf."},{"key":"10.1016\/j.jhep.2014.03.026_b0060","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2125.2005.02370.x","article-title":"Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database","volume":"60","author":"Russmann","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2014.03.026_b0065","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-3-642-00663-0_10","article-title":"Signal transduction pathways involved in drug-induced liver injury","author":"Han","year":"2010","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jhep.2014.03.026_b0070","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/hep.23720","article-title":"Pharmacogenetics of drug-induced liver injury","volume":"52","author":"Russmann","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.03.026_b0075","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1034\/j.1600-0676.2002.01718.x","article-title":"Allergic cholestatic hepatitis and exanthema induced by metamizole: verification by lymphocyte transformation test","volume":"22","author":"Herdeg","year":"2002","journal-title":"Liver"},{"key":"10.1016\/j.jhep.2014.03.026_b0080","doi-asserted-by":"crossref","first-page":"68","DOI":"10.7326\/0003-4819-135-1-200107030-00036","article-title":"Kava hepatotoxicity","volume":"135","author":"Russmann","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2014.03.026_b0085","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bcpt.12005","article-title":"Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry","volume":"112","author":"Gong","year":"2013","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jhep.2014.03.026_b0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bcpt.12084","article-title":"Role of P-glycoprotein in the uptake\/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model","volume":"113","author":"Gschwind","year":"2013","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jhep.2014.03.026_b0095","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/jpet.111.180240","article-title":"In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban","volume":"338","author":"Gnoth","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2014.03.026_b0100","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/jhep.2001.21083","article-title":"Causality assessment vs. guilt-by-association in drug hepatotoxicity","volume":"33","author":"Kaplowitz","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.03.026_b0105","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1665-2681(19)30888-9","article-title":"Drug induced liver injury: accuracy of diagnosis in published reports","volume":"13","author":"Teschke","year":"2014","journal-title":"Ann Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814002074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814002074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T17:12:07Z","timestamp":1748279527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827814002074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0168827814002074"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2014.03.026","relation":{},"ISSN":["0168-8278"],"issn-type":[{"type":"print","value":"0168-8278"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivaroxaban postmarketing risk of liver injury","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2014.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2014.05.010","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}